Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • threads
    • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Safety
    • Nurse Well-Being
    • Drug Reference Sheets
    • ONS Congress
    • Specific Populations
    View All Topics
    Advocacy
    • Latest Articles
    • Get Involved
    Stories View All
    View All
    cozy hospital room with bed and computer
    Interprofessional Issues
    Novel, Interprofessional Approach Enhances Bed Assignments for Individuals on Antineoplastic Drugs in a Hospital Setting
    August 22, 2024
    hand touching futuristic screen that represents artificial intelligence
    Nurse Empowerment
    How AI Can Support Oncology Nurses’ Spirit of Inquiry
    August 15, 2024
    person with brown clothes holding patient's hand in support on hospital bed
    Nurse Empowerment
    Sharing Our Stories Supports, Celebrates, and Advances the Nursing Profession
    July 04, 2024
    publish with ONS Voice
    Nursing Professional Development
    Publish Your First Article With ONS Voice
    March 19, 2024
    A family of nurses
    Nurse Well-Being
    When Health Care Is Woven in Our Family Fabric, We Find Support in Unexpected Places
    March 07, 2024
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
    • Home

    Author Content

    Oncology Drug Reference Sheet: Tocilizumab (Actemra®)
    COVID-19

    Oncology Drug Reference Sheet: Tocilizumab

    Tocilizumab was approved in August 2017 for the treatment of chimeric antigen receptor T cell–induced cytokine release syndrome. In March 2020, the U.S. Food and Drug Administration approved a randomized, double-blind, placebo-controlled, phase III clinical trial to assess the safety and efficacy of tocilizumab plus standard of care in patients hospitalized with severe COVID-19 pneumonia.

    April 14, 2020
    Emotional Coping Strategies for COVID-19
    Clinical Practice

    Emotional Coping Strategies for COVID-19

    The COVID-19 novel coronavirus pandemic is turning the world, inside and outside of the hospital, upside down. Not only are oncology nurses seeing high demands at work, but changes and restrictions are being instated at home as well.

    March 16, 2020
    COVID-19 Fact Sheet and Implications for Patients With Cancer
    Clinical Practice

    COVID-19 Fact Sheet and Implications for Patients With Cancer

    COVID-19 is a novel coronavirus (a large family of viruses that can cause cold-like illnesses) first identified in December 2019. It is a respiratory illness and can be spread from person to person through respiratory droplets during close contact. The first case of COVID-19 in the United States was reported on January 21, 2020.

    March 04, 2020
    Oncology Drug Reference Sheet: Niraparib

    Oncology Drug Reference Sheet: Niraparib

    Niraparib was approved in October 2019 for patients with homologous recombination deficiency (HRD)-positive advanced ovarian, fallopian tube, or primary peritoneal cancer. 

    February 25, 2020
    Oncology Drug Reference Sheet: Radium 223 Dichloride

    Oncology Drug Reference Sheet: Radium 223 Dichloride

    Radium 223 dichloride (Xofigo®) is an alpha particle-emitting radioactive therapeutic agent approved by the U.S. Food and Drug Administration in 2013 for castrate-resistant prostate cancer.

    December 24, 2019
    Beta Data Browser Puts Precision Medicine Cohort at Researchers’ Fingertips
    Oncology Nurse Scientist

    Beta Data Browser Puts Precision Medicine Cohort at Researchers’ Fingertips

    The future of cancer care is here: precision medicine has led to many of today’s newest cancer treatments and has made incredible progress since former President Barak Obama first announced the U.S. Precision Medicine Initiative (PMI) in 2015.

    June 27, 2019
    Combination Trastuzumab and Hyaluronidase-Oysk

    Oncology Drug Reference Sheet: Combination Trastuzumab and Hyaluronidase-Oysk

    A new product that combines trastuzumab and hyaluronidase (Herceptin Hylecta™) received U.S. Food and Drug Administration approval in February 2019 for the treatment of HER2-overexpressing breast cancer. The approval was based on the results of two randomized trials: HannaH and SafeHER. 

    June 18, 2019
    Which Ambulatory Infusion Pump Is Best for 5-FU?

    Which Ambulatory Infusion Pump Is Best for 5-FU?

    Because of its long infusion time over 46–48 hours, 5-fluorouracil (5-FU) is usually administered with an ambulatory infusion pump in the outpatient setting. However, two types of pumps exist. On one side of the spectrum is the elastomeric pump: small, compact, but gets the job done. On the other is the electronic pump: bigger, flashy, with lots of bells and whistles (literally). Here are the advantages and disadvantages of each.

    April 18, 2019
    Study Finds Three Priority Steps to Improve Cancer Survivorship
    Survivorship

    Study Finds Three Priority Steps to Improve Cancer Survivorship

    Healthcare providers need to address three priority areas to improve outcomes for cancer survivors and support caregivers for patients with cancer, according to findings from an evidence review published in CA: A Cancer Journal for Clinicians.

    January 23, 2019
    Oncology Drug Reference Sheet: Lutetium Lu 177 Dototate

    Oncology Drug Reference Sheet: Lutetium Lu 177 Dotatate

    Lutetium Lu 177 dototate (Lutathera®) was approved in January 2018 by the U.S. Food and Drug Administration to treat a specific group of neuroendocrine tumors (NETs) in the gastrointestinal tract. NETs are rare, and the tumors produce hormone-like substances in response to signals from the nervous system.

    January 23, 2019
    What APRNs Need to Know About Right to Try
    Advanced Practice Nursing (APRN)

    What APRNs Need to Know About Right to Try

    The Right-to-Try law, which has been in effect since May 2018, may have a misleading name, given that it doesn’t require drug manufacturers to grant access to experimental treatments that have passed phase I trials to any patient who seeks it. Rather, the law grants terminally ill patients the “right to ask” the drug company directly, but the request can be denied for several reasons (e.g., limited supply, expense).

    October 16, 2018
    TNM Gets an Upgrade in Eighth Edition Staging Guidelines
    Clinical Practice Guidelines

    TNM Gets an Upgrade in Eighth Edition Staging Guidelines

    Nearly a century ago, cancer staging was a simple categorization of disease as either local, regional, or distant. Then in the 1940s, a French surgeon developed the concept for a staging system that uses the size of the primary tumor (T), its lymphatic involvement (N), and the presence of metastases (M) to stage a patient’s cancer based on the anatomic extent of the disease at the time of diagnosis.

    August 09, 2018
    • First page « First
    • Previous page
    • Page 1
    • Current page 2

    To discuss the information in this article with other oncology nurses, visit the ONS Communities.

    To report a content error, inaccuracy, or typo, email pubONSVoice@ons.org.

    Chelsea Backler MSN, APRN, AGCNS-BC, AOCNS®, VA-BC
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Contact Us
  • Advertising
  • Newsroom
  • Conferences
  • RSS Feed
  • Sitemap
  • Legal Notices

    • Subscribe to ONS Voice Updates

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • threads
  • ONS
  • Oncology Nursing Foundation
  • ONCC
    • © Copyright 2024 Oncology Nursing Society
    Back to Top ▲